TABLE 3. Annual reported cases of notifiable diseases, by month*, excluding U.S. Territories - - United States, 2018 column labels in same order that data fields appears in each record below: Disease Jan. Feb. Mar. Apr. May June July Aug. Sept. Oct. Nov. Dec. Unknown Total tab delimited data: Anthrax — — — — — — — — 1 — — — — 1 Arboviral diseases, Chikungunya virus disease 7 4 4 11 9 11 18 17 13 9 4 10 — 117 Arboviral diseases, Eastern equine encephalitis virus disease, Neuroinvasive — — — — — 2 — 2 1 1 — — — 6 Arboviral diseases, Eastern equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — Arboviral diseases, Jamestown Canyon virus disease, Neuroinvasive — — — 1 2 2 5 4 6 5 — — — 25 Arboviral diseases, Jamestown Canyon virus disease, Non-neuroinvasive — — — — 1 3 5 1 4 — 1 1 — 16 Arboviral diseases, La Crosse virus disease, Neuroinvasive — — — — — 3 17 24 21 14 3 1 — 83 Arboviral diseases, La Crosse virus disease, Non-neuroinvasive — — — — — 1 — — 2 — — — — 3 Arboviral diseases, Powassan virus disease, Neuroinvasive — — 1 1 2 5 6 — 1 2 2 1 — 21 Arboviral diseases, Powassan virus disease, Non-neuroinvasive — — — — — — — — — — — — — — Arboviral diseases, St. Louis encephalitis virus disease, Neuroinvasive — — — — — — — 1 1 2 1 — — 5 Arboviral diseases, St. Louis encephalitis virus disease, Non-neuroinvasive — — — — — — 2 — — 1 — — — 3 Arboviral diseases, West Nile virus disease, Neuroinvasive 2 2 — 2 3 4 146 546 710 160 58 24 — 1,657 Arboviral diseases, West Nile virus disease, Non-neuroinvasive — — 1 1 3 9 146 354 406 48 12 9 — 989 Arboviral diseases, Western equine encephalitis virus disease, Neuroinvasive — — — — — — — — — — — — — — Arboviral diseases, Western equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — Babesiosis, Total 10 17 16 15 39 385 682 412 222 104 75 183 — 2,160 Babesiosis, Confirmed 8 10 11 9 26 327 601 372 184 91 63 159 — 1,861 Babesiosis, Probable 2 7 5 6 13 58 81 40 38 13 12 24 — 299 Botulism, Total 17 14 19 18 14 21 13 16 22 20 21 30 — 225 Botulism, Foodborne 1 — — 2 — 3 3 — 1 1 1 5 — 17 Botulism, Infant 14 11 17 11 10 12 6 12 11 15 17 21 — 157 Botulism, Other (wound & unspecified) 2 3 2 5 4 6 4 4 10 4 3 4 — 51 Brucellosis 3 5 14 17 15 14 10 12 14 6 14 14 — 138 Campylobacteriosis 3,244 3,321 4,836 4,699 5,407 9,038 7,607 6,864 7,124 5,220 4,796 8,044 — 70,200 Chancroid — — 1 1 — — — 1 — — — — — 3 Chlamydia trachomatis infection 126,499 134,590 169,317 136,608 135,445 163,507 131,200 144,821 176,966 141,520 128,844 169,351 — 1,758,668 Cholera — 2 — — 1 1 1 — 4 2 1 2 — 14 Coccidioidomycosis † 1,880 1,304 1,389 995 1,131 1,356 1,197 1,160 1,354 1,211 1,127 1,507 — 15,611 Cryptosporidiosis, Total 539 533 780 779 795 1,202 1,452 1,768 1,774 1,023 781 1,107 — 12,533 Cryptosporidiosis, Confirmed 347 328 508 512 521 854 1,100 1,316 1,351 765 566 812 — 8,980 Cryptosporidiosis, Probable 192 205 272 267 274 348 352 452 423 258 215 295 — 3,553 Cyclosporiasis 4 7 15 22 148 1,147 1,639 325 113 26 20 53 — 3,519 Dengue virus infections, Dengue § 19 9 5 13 14 20 49 56 47 50 70 72 — 424 Dengue virus infections, Dengue-like illness § 2 1 — 2 — 3 2 6 8 3 6 8 — 41 Dengue virus infections, Severe dengue § — — — — — — 1 — 2 2 2 2 — 9 Diphtheria — — — — — — — — — 1 — — — 1 Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection 15 30 40 93 414 1,202 762 424 378 246 227 177 — 4,008 Ehrlichiosis and Anaplasmosis, Ehrlichia chaffeensis infection 7 15 22 37 136 464 376 227 211 88 47 169 — 1,799 Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection — — — — 1 8 13 3 4 2 2 — — 33 Ehrlichiosis and Anaplasmosis, Undetermined ehrlichiosis/anaplasmosis 3 1 8 8 23 78 54 31 30 20 16 11 — 283 Giardiasis 929 1,021 1,338 994 1,039 1,338 1,334 1,638 1,974 1,266 1,005 1,672 — 15,548 Gonorrhea 42,421 41,729 51,973 42,765 43,558 55,240 45,523 48,239 60,385 48,206 44,278 59,088 — 583,405 Haemophilus influenzae, invasive disease, All ages, all serotypes 555 478 582 441 425 556 365 299 428 351 369 724 — 5,573 Haemophilus influenzae, invasive disease, Age <5 years, Serotype b 3 3 1 5 5 8 1 2 2 2 1 5 — 38 Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype 13 25 21 17 13 14 13 5 15 10 14 31 — 191 Haemophilus influenzae, invasive disease, Age <5 years, Nontypeable 18 29 27 14 18 23 7 13 17 14 15 27 — 222 Haemophilus influenzae, invasive disease, Age <5 years, Unknown serotype 14 11 17 18 14 14 10 9 13 8 13 34 — 175 Hansen's disease 4 7 8 5 7 10 4 19 6 11 4 5 — 90 Hantavirus infection, non-hantavirus pulmonary syndrome — — — — — — — 2 — — — — — 2 Hantavirus pulmonary syndrome 1 1 2 1 1 2 2 1 3 1 1 2 — 18 Hemolytic uremic syndrome post-diarrheal 9 3 20 31 34 45 59 34 56 24 39 22 — 376 Hepatitis, A, acute ¶ 249 295 411 486 524 1,101 1,011 1,228 1,702 1,538 1,565 2,364 — 12,474 Hepatitis, B, acute ¶ 206 247 291 260 219 316 264 256 339 261 249 414 — 3,322 Hepatitis, B, perinatal infection ¶ 3 3 2 2 2 — 3 3 — — 2 3 — 23 Hepatitis, C, acute ¶ 293 326 418 357 432 428 336 373 544 355 296 610 — 4,768 Hepatitis, C, acute, Confirmed ¶ 250 277 347 290 332 344 266 269 333 255 213 445 — 3,621 Hepatitis, C, acute, Probable ¶ 43 49 71 67 100 84 70 104 211 100 83 165 — 1,147 Hepatitis, C, perinatal infection ¶ 15 20 24 20 25 22 8 9 22 13 12 24 — 214 Human immunodeficiency virus diagnoses 3,151 2,894 3,225 3,004 3,224 3,173 3,176 3,264 2,734 2,848 1,788 517 1 32,999 Influenza-associated pediatric mortality 36 53 24 18 9 4 — 2 1 4 1 7 — 159 Invasive pneumococcal disease, All ages ** 2,820 2,386 2,417 1,892 1,565 1,340 741 621 993 1,059 1,263 2,760 — 19,857 Invasive pneumococcal disease, All ages, Confirmed ** 2,789 2,364 2,383 1,874 1,549 1,325 725 611 981 1,048 1,242 2,728 — 19,619 Invasive pneumococcal disease, All ages, Probable ** 31 22 34 18 16 15 16 10 12 11 21 32 — 238 Invasive pneumococcal disease, Age <5 years ** 101 122 132 91 85 92 36 37 78 84 91 167 — 1,116 Invasive pneumococcal disease, Age <5 years, Confirmed ** 98 118 126 90 84 89 32 35 77 82 87 160 — 1,078 Invasive pneumococcal disease, Age <5 years, Probable ** 3 4 6 1 1 3 4 2 1 2 4 7 — 38 Legionellosis 313 280 392 256 387 1,233 1,046 1,311 1,664 1,384 738 929 — 9,933 Leptospirosis 6 4 6 2 4 10 7 7 24 6 4 11 — 91 Listeriosis 31 39 57 48 44 86 88 119 108 76 72 96 — 864 Lyme disease, Total 996 1,112 1,306 1,282 2,018 6,171 6,782 4,549 3,330 2,270 1,792 2,058 — 33,666 Lyme disease, Confirmed 647 706 802 808 1,275 4,424 5,023 3,296 2,329 1,574 1,273 1,401 — 23,558 Lyme disease, Probable 349 406 504 474 743 1,747 1,759 1,253 1,001 696 519 657 — 10,108 Malaria 99 89 78 117 135 223 152 197 240 145 98 175 — 1,748 Measles, Total 10 5 28 29 13 13 13 12 9 43 72 128 — 375 Measles, Indigenous 5 2 21 19 6 4 7 8 5 28 70 121 — 296 Measles, Imported 5 3 7 10 7 9 6 4 4 15 2 7 — 79 Meningococcal disease, All serogroups 37 38 38 21 26 21 21 14 21 20 23 47 — 327 Meningococcal disease, Serogroups ACWY 11 10 11 10 7 8 7 3 5 9 10 9 — 100 Meningococcal disease, Serogroup B 9 12 9 5 7 5 8 5 6 6 6 3 — 81 Meningococcal disease, Other serogroups 3 4 5 — 1 — — — 4 1 3 2 — 23 Meningococcal disease, Unknown serogroup 14 12 13 6 11 8 6 6 6 4 4 33 — 123 Mumps 266 298 352 245 286 137 100 127 128 135 124 317 — 2,515 Novel Influenza A virus infections — — — — — 1 — 13 — — — — — 14 Paratyphoid fever †† 13 10 12 12 9 12 13 11 17 7 8 9 — 133 Pertussis 1,013 988 1,219 1,100 1,294 1,509 1,233 1,114 1,322 1,085 1,280 2,452 — 15,609 Plague — — — — — 1 — — — — — — — 1 Poliomyelitis, paralytic — — — — — — — — — — — — — — Poliovirus infection, nonparalytic — — — — — — — — — — — — — — Psittacosis — — 3 1 — 2 — 1 9 3 1 2 — 22 Q fever, Total 10 9 32 26 26 20 16 20 18 7 11 20 — 215 Q fever, Acute 8 6 30 22 20 17 13 18 16 7 9 12 — 178 Q fever, Chronic 2 3 2 4 6 3 3 2 2 — 2 8 — 37 Rabies, Animal 213 225 405 445 483 418 543 728 566 466 277 215 — 4,984 Rabies, Human 1 — — — — — — — 1 1 — — — 3 Rubella — — 1 — 1 — — — — 2 — — — 4 Rubella, congenital syndrome — — — — — — — — — — — — — — Salmonellosis (excluding paratyphoid fever and typhoid fever) §§ 2,112 2,489 3,227 3,014 3,783 6,710 6,813 7,345 9,233 6,091 4,264 5,918 — 60,999 Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — — Shiga toxin-producing Escherichia coli (STEC) 553 574 975 1,172 1,184 2,164 1,887 1,867 1,744 1,219 917 1,740 — 15,996 Shigellosis 855 796 1,279 1,013 1,123 1,588 1,503 1,643 1,719 1,365 1,403 2,046 — 16,333 Smallpox — — — — — — — — — — — — — — Spotted fever rickettsiosis, Total 53 57 175 239 516 1,338 929 742 766 346 175 208 — 5,544 Spotted fever rickettsiosis, Confirmed 1 2 6 9 12 33 19 13 16 3 2 8 — 124 Spotted fever rickettsiosis, Probable 52 55 169 230 504 1,305 910 729 750 343 173 200 — 5,420 Streptococcal toxic shock syndrome 50 45 55 31 26 34 29 18 14 12 24 33 — 371 Syphilis, Total, all stages ¶¶ 8,162 8,731 11,132 9,134 8,884 10,756 8,664 9,113 11,591 9,302 8,532 11,044 — 115,045 Syphilis, Congenital 107 84 106 95 89 105 115 112 136 128 116 113 — 1,306 Syphilis, Primary and secondary 2,413 2,581 3,354 2,750 2,685 3,326 2,767 2,736 3,700 2,850 2,634 3,267 — 35,063 Tetanus — — — 3 4 2 1 5 1 2 3 2 — 23 Toxic shock syndrome (other than Streptococcal) — 6 2 2 3 4 2 2 2 3 4 3 — 33 Trichinellosis — — — — 1 — — — — — — — — 1 Tuberculosis 506 587 770 766 770 817 717 853 636 789 737 1,077 — 9,025 Tularemia — 2 3 7 22 42 54 32 15 25 5 22 — 229 Typhoid fever 28 23 34 36 35 24 28 43 61 23 8 58 — 401 Vancomycin-intermediate Staphylococcus aureus 5 8 13 3 8 10 7 2 6 5 7 11 — 85 Vancomycin-resistant Staphylococcus aureus — — — — — — — — — — — — — — Varicella morbidity 512 577 791 685 761 769 493 506 824 639 646 998 — 8,201 Varicella mortality — 1 2 — 1 1 1 — — — — — — 6 Vibriosis, Total 63 84 128 131 118 324 400 507 389 234 166 420 — 2,964 Vibriosis, Confirmed 29 38 63 56 68 229 275 355 240 137 84 248 — 1,822 Vibriosis, Probable 34 46 65 75 50 95 125 152 149 97 82 172 — 1,142 Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Ebola virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Guanarito virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Junin virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lassa virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lujo virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Machupo virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Marburg virus — — — — — — — — — — — — — — Viral hemorrhagic fevers, Sabia virus — — — — — — — — — — — — — — Yellow fever — — — — — — — — — — — — — — Zika virus, Zika virus disease, congenital *** — — — — 1 — — 1 — — — — — 2 Zika virus, Zika virus disease, non-congenital 12 7 7 6 2 3 11 10 4 8 4 5 — 79 Zika virus, Zika virus infection, congenital *** 2 2 1 — 1 — — — — 1 — 1 — 8 Zika virus, Zika virus infection, non-congenital 18 28 21 31 19 14 14 14 23 19 11 33 — 245 —: No reported cases - The reporting jurisdiction did not submit any cases to CDC. * Month is defined using MMWR week (http://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf). MMWR week calendars can be found at http://wwwn.cdc.gov/nndss/script/downloads.aspx. † Reportable in <25 states. § Counts include confirmed and probable dengue cases. ¶ Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. ** Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years. †† Prior to 2018, cases of paratyphoid fever were considered salmonellosis. §§ Prior to 2018, cases of paratyphoid fever were included as salmonellosis, but beginning in 2018 they are being published as paratyphoid fever. ¶¶ Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); and unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations). *** Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01). Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the https://ndc.services.cdc.gov/, Surveillance Case Definitions | CDC web page, selecting "2018" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2017 by CSTE for national surveillance, that were implemented in January 2018, including updated surveillance case definitions for anthrax, shiga toxin-producing Escherichia coli, and syphilis. Perinatal hepatitis c virus infection became a new nationally notifiable condition in 2018. While Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) was added to the list of nationally notifiable diseases in 2018, reporting jurisdictions could not submit data for this condition since Office of Management and Budget Paperwork Reduction Act approval was pending during 2018. Publication criteria for the finalized 2018 data are available at https://wonder.cdc.gov/nndss/documents/2018_NNDSS _Publication_Criteria_07122019_updated_09230219.pdf, https://wonder.cdc.gov/nndss/documents/2018_NNDSS _Publication_Criteria_07122019_updated_09230219.pdf. See also https://ndc.services.cdc.gov/wp-content/uploads/Users_guide_WONDER_tables_cleared_final.pdf, Guide to Interpreting Provisional and Finalized NNDSS Data. Annual tables for 2016 and later years are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993-2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, MMWR. NNDSS annual tables since 1952 are available at https://stacks.cdc.gov/nndss, CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left). For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a nationally notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations. Population estimates for incidence rates are July 1st, 2018 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2018, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2018), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 25, 2019 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm, https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2018 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on June 26, 2019 at https://www.census.gov/data-tools/demo/idb/informationGateway.php, https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. Age restrictions in the numerator and denominator are applied for the following childhood conditions: Zika virus disease, congenital (age restriction in numerator and denominator is <1 year) Zika virus infection, congenital (age restriction in numerator and denominator is <1 year) Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years) Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years) Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years) Infant botulism (age restriction in numerator and denominator is <1 year) Congenital rubella syndrome (age restriction in numerator and denominator is <1 year) Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months) Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months) Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2018 (National Center for Health Statistics https://wonder.cdc.gov/natality.html, Natality 2018, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the Sexually Transmitted Diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm, https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm, https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm, https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC). Suggested Citation: Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2018 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2019. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html, https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html. Acknowledgement: CDC acknowledges the Local, State, and Territorial Health Departments that collected the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System. https://www.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER